Manufacturing

Articles

The UK Stem Cell Bank released validated stem-cell lines for researchers developing novel cell-based therapies for clinical trials.

UKSCB Releases Stem Cell Lines for Development

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Researchers from Cellectis investigate how external signals in the tumor microenvironment could control the cell-surface expression and specificity of engineered CARs.

Cellectis Describes Novel CAR-T Design in New Paper

Language surrounding regenerative medicine and the REGROW Act appeared back into the 21st Century Cures Act right before it passed. What will this mean for the controversial testing and marketing of stem-cell therapies?

How Tightly Should Stem-Cell Therapies Be Regulated by FDA?

Oxford Genetics received £1.61 million from Innovate UK to explore computational and synthetic biology approaches for optimized mammalian bioproduction.

Oxford Genetics Receives Grant from Innovate UK

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

At the American Society of Hematology Annual Meeting, Novartis and Kite Pharma both released results from early-phase clinical trials with CAR-T therapies.

Novartis, Kite Release Positive CAR-T Data

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.

FDA Tackles Cellular, Gene Therapies

The acquisition will add to the company's cell therapy base and potential impact in treating rare diseases.

Pfizer Shores Up Cell Therapy With Acquisition of Bamboo Therapeutics

The collaboration will focus on the investigational candidate JTX-2011 and up to four other early-stage programs in immune-oncology.

Celgene Partners with Jounce Therapeutics for Immunotherapy Development

GE further ramps up its cellular and gene therapy offerings with its acquisition of Biosafe, a cell processing solutions company.

GE Healthcare Focuses on Cell Therapies with BioSafe Acquisition

A research team associated with Dr. Carl June announces it has discovered a way to engineer a patient’s own immune cells to recognize cancer-specific glycoantigens on tumor cells.

Manufacturing, Cell Therapies